Provisional CDC estimates showed the suicide rate last year reached a record high since 1941 and was an age-adjusted 1% higher than in 2021.
The FDA accepted Karuna Therapeutics’ new drug application for its investigational schizophrenia treatment xanomeline-trospium (KarXT) along with the EMERGENT clinical trial data, with a decision expected by September 2024.
Two doses of XEN1101 flopped in a mid-stage trial of people with moderate-to-severe major depressive disorder, said Xenon Pharmaceuticals.
Meanwhile, BioVie blamed clinical trial site protocol deviations as the reason why its investigational Alzheimer’s disease drug NE3107 failed a phase III trial.
In the randomized SELFIE trial from Germany, a novel transdiagnostic ecological momentary intervention demonstrated efficacy on self-esteem outcomes. (JAMA Psychiatry)
Only 39% of young adults ages 18 to 24 remained on their ADHD treatment for at least 5 years. (The Lancet Psychiatry)
The American Psychological Association issued a new report detailing the psychology of misinformation and how to combat it.
Breast cancer screening completion was lower among women with schizophrenia, a case-control study in Canada showed. (JAMA Network Open)
The PSYCHE study found that mothers with breast cancer were susceptible to both depression and parenting stress. (JAMA Network Open)
Serious clozapine-related neutropenia that led to medication cessation usually occurred within 18 weeks of starting treatment, a retrospective study found. (The Lancet Psychiatry)
Adults who had a health checkup with depression screening had a higher rate of newly treated depression and a lower risk of psychiatric hospitalization than their unscreened counterparts, a study from Taiwan found. (The Lancet Regional Health Western Pacific)
Nurses at Seattle Children’s Hospital asked for immediate help following reports of violence at the Psychiatry and Behavioral Medicine Unit. (Washington State Nurses Association)